GENE ONLINE|News &
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
In a flurry of highs and lows for Biogen this week, the company voluntarily paid a $900 million settlement in a lawsuit brought about by a former employee regarding alleged paid kickbacks for physicians willing to prescribe the company’s multiple sclerosis drugs. At the other end of Biogen’s week, the company reported positive Phase 3 confirmatory trial results from its newest Alzheimer’s drug developed with Eisai, lecanemab, which is set for a regulatory decision in January next year.
It's free! Log in now to read
LATEST
NUS Researchers Use Evolutionary Biology Models to Map Singapore Shophouse Architectural Development
2026-08-11
City St George’s Launches €6 Million REMADE Project to Advance Circular Renovation in Urban Neighborhoods
2026-08-10
Digital Science Releases Two Model Context Protocol Servers for Dimensions Research Platform
2026-08-10
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
